Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2020-10-01 Regulatory Filings
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market
Regulatory Filings Classification · 98% confidence The document is a formal announcement dated October 1, 2020, originating from DiaSorin, detailing that its LIAISON SARS-CoV-2 IgM test received FDA Emergency Use Authorization (EUA). The metadata indicates the document length is relatively short (4940 characters) and the text itself contains a section 'Vedi allegato' (See attachment) and is structured as a press release announcing a regulatory event (FDA EUA). This structure strongly suggests it is a regulatory announcement rather than a comprehensive report (like 10-K or IR). Since it is a specific regulatory update that doesn't fit the definitions for Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate general category for a significant, non-periodic regulatory event announcement that isn't a standard financial report is Regulatory Filings (RNS). Although it is an announcement, RNS serves as the best fit for miscellaneous regulatory news that isn't explicitly covered by other codes.
2020-10-01 English
DiaSorin riceve l’approvazione ad uso di emergenza dalla Food and Drug Administration americana per il test LIAISON SARS-CoV-2 IgM negli Stati Uniti
Regulatory Filings Classification · 98% confidence The document is a formal announcement dated October 1, 2020, originating from DiaSorin, classified as 'Informazione Regolamentata' (Regulated Information) with the type 'REGEM'. The subject is receiving Emergency Use Authorization (EUA) from the US FDA for a COVID-19 test. This is a specific, material event announcement that is not a periodic financial report (like 10-K or IR), a transcript (CT), or a management discussion (MDA). It is a general regulatory disclosure concerning a significant operational/product development milestone. Since it is a specific regulatory announcement that doesn't fit the other specialized categories (like DIRS, DIV, CAP, etc.), the most appropriate general category for significant, non-financial, non-meeting related regulatory news is 'Regulatory Filings' (RNS). The document length is moderate (5820 chars), suggesting it is the full announcement, not just a placeholder for a report.
2020-10-01 Italian
DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China
Regulatory Filings Classification · 95% confidence The document is an official announcement dated September 23, 2020, originating from DiaSorin. The subject line and content clearly describe a strategic business development: extending a joint venture with the Chinese Government to establish a new manufacturing and research site in Shanghai. This type of announcement, detailing significant corporate actions, partnerships, or strategic moves that are not standard periodic financial reports (like 10-K or IR) or routine administrative filings (like DIRS or DIV), fits best under the category of a general regulatory announcement or a significant corporate event disclosure. Since the text is a full announcement detailing the event and includes contact information, it is not merely an announcement *of* a report (RPA). Given the options, it is a significant corporate action disclosure. While it relates to capital/financing indirectly through expansion, the core is a strategic partnership/expansion. It is not a standard SEC filing like 10-K or ER. It is a formal regulatory disclosure ('Informazione Regolamentata'). This type of material, detailing strategic business expansion and partnership agreements, often falls under general regulatory news. Since there isn't a specific 'Strategic Partnership' code, and it's a formal, non-periodic disclosure, the most appropriate general regulatory category is RNS (Regulatory Filings), which serves as a fallback for significant, non-standard announcements not covered by other specific codes like M&A (TAR) or Capital Change (CAP). However, looking closely at the definitions, it is a major corporate development announcement. If we consider the nature of the news (major expansion/JV extension), it is a significant corporate event. Since it is not a specific financial report, a management change, or a shareholder vote result, RNS is the best fit as a general regulatory disclosure.
2020-09-23 English
DiaSorin estende l’attuale joint-venture con il Governo cinese per l’apertura del nuovo impianto produttivo e di ricerca in Cina
Regulatory Filings Classification · 99% confidence The document is structured as an official regulatory announcement ('Informazione Regolamentata n. 0957-83-2020', 'Tipologia: REGEM') dated September 23, 2020. The subject ('Oggetto') is the extension of a joint venture concerning a new production and research facility in China. The text details a significant business development (M&A/Partnership activity) but is presented as a brief press release or official notice, concluding with 'Vedi allegato' (See attachment) and contact information, rather than being a comprehensive financial report (like 10-K or IR) or a transcript (CT). Since it announces a major strategic transaction (joint venture extension/investment), it falls under the scope of major corporate actions. While 'TAR' (M&A Activity) is a possibility, the document is primarily a formal regulatory disclosure about a strategic business move that doesn't explicitly detail a takeover bid or merger proposal, but rather an investment/partnership extension. Given the nature of the announcement—a significant strategic business update released via a regulated channel—and the lack of a specific category for strategic partnership announcements, the most appropriate general category for significant, non-standard regulatory news that isn't purely financial reporting or management change is 'RNS' (Regulatory Filings) as a fallback, or potentially 'TAR' if the joint venture extension is considered a form of M&A activity. However, since it is a formal, regulated announcement ('REGEM') detailing a strategic business development, and it is not a standard financial report, 'RNS' is the safest classification for a general regulatory disclosure that doesn't fit the other specific codes. The document length is moderate (6494 chars), but its format is that of a notification, not the full underlying report.
2020-09-23 Italian
Update Annual Calendar of Corporate Events 2020
Report Publication Announcement Classification · 99% confidence The document is a formal regulatory announcement (indicated by 'Informazione Regolamentata' and 'REGEM' type) from DiaSorin S.p.A. The subject ('Oggetto') is 'Update Annual Calendar of Corporate Events 2020'. The content details future dates for Board of Directors meetings related to results approvals (e.g., Third Quarter 2020 results approval on November 11th, 2020). This type of communication, which announces the schedule of future corporate events, investor meetings, or report releases, fits best under the general category of regulatory announcements that do not correspond to a specific financial report or transaction type. Since it is an announcement about future corporate events/schedules rather than the release of a specific report (like 10-K, ER, or IR), and it doesn't fit other specific codes (like DIV, DIRS, MANG), the most appropriate classification is the general regulatory filing fallback category, RNS.
2020-09-16 English
Aggiornamento Calendario Annuale Eventi Societari 2020
Regulatory Filings Classification · 95% confidence The document is a formal announcement from DiaSorin S.p.A. dated September 16, 2020, titled 'Aggiornamento Calendario Annuale Eventi' (Update to the Annual Event Calendar). It specifically details future dates for board meetings related to financial data approvals (e.g., Third Quarter 2020 data approval on November 11, 2020) and mentions that conference calls will follow. This document is not the actual financial report (like an IR or 10-K), nor is it a transcript (CT) or a dividend notice (DIV). It is an announcement about the schedule of future corporate events, including financial reporting releases and associated calls. Since it announces the timing and nature of future corporate events/reports, it fits best under the general category of Regulatory Filings (RNS) or potentially a Report Publication Announcement (RPA) if it were announcing the immediate release of a report. Given the content is purely scheduling updates for the remainder of the year, RNS is the most appropriate general regulatory filing category for scheduling announcements that don't fit specific categories like DIV or ER.
2020-09-16 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.